Drug Trial Radar · NCT06185205
ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
170
Planned (sponsor's estimate)
Start
Dec 12, 2023
Primary completion
Jan 31, 2031
Study completion Jan 31, 2033
Sponsor
- Lead sponsor
- Virginia Commonwealth UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 29, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 45 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare any good and bad effects of giving radiation treatment for breast cancer in 3 treatments over about 2 days.
Conditions
- Breast Cancer
Interventions
Accelerated partial breast irradiationDrug
High Dose Rate treatment delivery
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess the toxicity (at 1 and 3 years) of a 1.5-day APBI treatment courseTime frame: 1 year, and 5 years following irradiation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Virginia Commonwealth University
Richmond, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.